tradingkey.logo

Supernus Pharmaceuticals Inc

SUPN

36.471USD

+0.966+2.72%
交易中 美东报价延迟15分钟
2.04B总市值
32.98市盈率 TTM

Supernus Pharmaceuticals Inc

36.471

+0.966+2.72%
关于 Supernus Pharmaceuticals Inc 公司
Supernus Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于开发和商业化用于治疗中枢神经系统 (CNS) 疾病的产品。其多样化的神经科学产品组合包括已获批的治疗癫痫、偏头痛、注意力缺陷多动障碍 (ADHD)、帕金森病 (PD) 中的运动障碍、颈部肌张力障碍、慢性流涎症、接受左旋多巴治疗的 PD 患者的运动障碍以及成人患者药物引起的锥体外系反应的药物。该公司还在开发一系列新型 CNS 产品候选药物,包括用于治疗 PD 中的运动障碍、癫痫、抑郁症和其他 CNS 疾病的新潜在疗法。其商业产品包括 Qelbree(维洛沙嗪)、GOCOVRI(金刚烷胺)、Oxtellar XR(奥卡西平)、Trokendi XR(托吡酯)、APOKYN(盐酸阿扑吗啡注射液)等。 Qelbree(维洛沙嗪)是一种新型非兴奋剂产品,用于治疗 ADHD。
公司简介
公司代码SUPN
公司名称Supernus Pharmaceuticals Inc
上市日期Dec 28, 2010
CEOMr. Jack A. Khattar
员工数量674
证券类型Ordinary Share
年结日Dec 28
公司地址9715 Key West Avenue
城市ROCKVILLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编20850
电话13018382500
网址https://www.supernus.com
公司代码SUPN
上市日期Dec 28, 2010
CEOMr. Jack A. Khattar
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
12.68K
+7.65%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
9.63K
+8.32%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
地区USD
名称
营收
占比
United States
149.82M
100.00%
业务
地区
业务USD
名称
营收
占比
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
股东统计
更新时间: 5月8日 周四
更新时间: 5月8日 周四
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
股东类型
持股股东
占比
Investment Advisor
56.83%
Investment Advisor/Hedge Fund
30.46%
Hedge Fund
15.36%
Individual Investor
4.11%
Research Firm
2.96%
Pension Fund
1.70%
Venture Capital
0.93%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.27%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
563
63.74M
113.85%
-2.63M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
2023Q1
539
59.34M
108.94%
-3.56M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.20M
14.65%
-297.23K
-3.50%
Mar 31, 2025
The Vanguard Group, Inc.
6.15M
10.99%
+13.13K
+0.21%
Mar 31, 2025
Armistice Capital LLC
5.20M
9.28%
+360.00K
+7.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.90M
5.19%
+25.18K
+0.87%
Mar 31, 2025
Macquarie Investment Management
2.70M
4.82%
+70.76K
+2.69%
Mar 31, 2025
State Street Global Advisors (US)
2.15M
3.83%
-42.85K
-1.96%
Mar 31, 2025
Khattar (Jack A)
2.01M
3.6%
--
--
Apr 22, 2025
Renaissance Technologies LLC
1.59M
2.83%
-13.00K
-0.81%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.74M
3.1%
-13.59K
-0.78%
Mar 31, 2025
Loomis, Sayles & Company, L.P.
1.44M
2.57%
-26.38K
-1.80%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.1%
Invesco Pharmaceuticals ETF
2.62%
SPDR S&P Pharmaceuticals ETF
2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.45%
Invesco S&P SmallCap Health Care ETF
1.26%
Lattice Hartford Multifactor Small Cap ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.65%
VictoryShares Small Cap Free Cash Flow ETF
0.47%
Distillate Small/Mid Cash Flow ETF
0.47%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.1%
Invesco Pharmaceuticals ETF
占比2.62%
SPDR S&P Pharmaceuticals ETF
占比2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.45%
Invesco S&P SmallCap Health Care ETF
占比1.26%
Lattice Hartford Multifactor Small Cap ETF
占比0.93%
iShares U.S. Pharmaceuticals ETF
占比0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
占比0.65%
VictoryShares Small Cap Free Cash Flow ETF
占比0.47%
Distillate Small/Mid Cash Flow ETF
占比0.47%
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
tradingkey.logo
tradingkey.logo
日内数据由路孚特(Refinitiv)提供,并受使用条款约束。历史及当前收盘数据均由路孚特提供。所有报价均以当地交易所时间为准。美股报价的实时最后成交数据仅反映通过纳斯达克报告的交易。日内数据延迟至少15分钟或遵循交易所要求。
* 参考、分析和交易策略由第三方提供商Trading Central提供,观点基于分析师的独立评估和判断,未考虑投资者的投资目标和财务状况。
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有
KeyAI